PubMed · 1998 · 162 citations · 33 references
Life SciencesCell BiologyImmunologyApoptosisInflammationInnate ImmunityDeath ReceptorsExtrinsic Apoptotic PathwayInflammatory Cell ResponsesInflammatory SignalingNeutrophil BiologyPhagocyte BiologyChemotactic Cell RecruitmentChemotactic MediatorsChemotactic SignalingDeath Ligand SignalingFas LigandFas Receptor SignalingFas-associated Death Domain ProteinImmune Cell Chemotaxis Assays
A recombinant soluble form of human Fas ligand (sFasL) was tested for its chemotactic activity against human and mouse polymorphonuclear neutrophils (PMN) by the Boyden chamber method. sFasL exhibited a potent chemotactic activity against both human and mouse PMN and HL-60 cells when differentiated into neutrophils or monocytes. A neutralizing anti-FasL mAb abolished the chemotactic activity, while control mAb did not. Ligation of Fas by either IgM- or IgG-type anti-Fas mAb also induced PMN migration. PMN derived from lpr mice that express few Fas molecules did not respond to sFasL. In contrast, those derived from lpr(cg) mice that express Fas molecules with a mutated death domain normally responded to sFasL chemotaxis. These results directly indicated a chemotactic activity of sFasL against PMN and suggest a novel signaling function of Fas, which appears to be independent of the death domain-mediated apoptosis.
33
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Thomas S. Griffith, Thomas Brunner, Sharon M. Fletcher et al. · Science · 1995 · 2K citations
Medicine, Immunology, Ophthalmology +17
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Michael Hahne, Donata Rimoldi, Michael Schröter et al. · Science · 1996 · 1.3K citations
Life Sciences, Immunology, Oncology +17
A role for CD95 ligand in preventing graft rejection
Donald Bellgrau, Daniel P. Gold, Helena Selawry et al. · Nature · 1995 · 1.2K citations